Cjc-1295 ipamorelin dosage

The strongest dosing data for CJC-1295 combined with ipamorelin comes from veterinary trials and unpublished protocols used in age management clinics — not controlled human studies. Most published human growth hormone secretagogue work focuses on single agents, leaving combination regimens in a gray zone of inferred benefit and practitioner consensus rather than rigorous evidence.

What CJC-1295 and Ipamorelin Are, and Why They're Paired

CJC-1295 DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a molecular weight of 3647.28 Da. The defining feature: a lysine residue modified with maleimidoproprionic acid, which allows the peptide to bind serum albumin and extend its half-life to roughly 6-8 days. This turns a naturally short-lived signaling peptide into a long-acting agent that maintains elevated growth hormone-releasing hormone signaling between doses.

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, 711.85 Da) that acts as a growth hormone secretagogue — it binds the ghrelin receptor (GHS-R1a) in the pituitary and triggers pulsatile growth hormone release. Unlike older secretagogues such as GHRP-6 or GHRP-2, ipamorelin does not significantly raise cortisol, prolactin, or ACTH at effective doses, which reduces potential side effects tied to non-selective receptor activation.

The rationale for combining them: CJC-1295 provides sustained GHRH signaling (the "releaser"), while ipamorelin delivers intermittent GHS-R1a stimulation (the "pulse generator"). This dual-axis activation theoretically mimics natural growth hormone dynamics more closely than either agent alone. In practice, the combination is popular in research and clinical protocols, but direct head-to-head human trial data comparing the stack to monotherapy are absent from the peer-reviewed literature.

How the Two Peptides Signal Through Different Receptors

CJC-1295 binds the growth hormone-releasing hormone receptor (GHRH-R), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Activation of GHRH-R triggers adenylyl cyclase, raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). This cascade increases transcription of the growth hormone gene and stimulates vesicular release of stored growth hormone into circulation. Because CJC-1295 stays bound to albumin and cycles through the receptor over days, it maintains baseline elevation of GHRH signaling rather than producing sharp peaks.

Ipamorelin acts at GHS-R1a, the ghrelin receptor, which is also a G-protein-coupled receptor but signals through a different pathway. GHS-R1a activation primarily engages Gq/11 proteins, raising intracellular calcium and activating phospholipase C. This produces a more immediate, pulse-like release of growth hormone. Crucially, ipamorelin's selectivity for GHS-R1a over related receptors means it avoids the appetite stimulation and cortisol spikes seen with less selective compounds like GHRP-6.

The combination works because the two receptors are expressed on the same pituitary cells but trigger growth hormone release through distinct intracellular machinery. GHRH-R activation primes the somatotroph, while GHS-R1a activation delivers the release signal. Rodent studies from the late 1990s (Beck et al., Endocrinology, 1998) showed that co-administration of GHRH analogues and GHS-R1a agonists produced synergistic growth hormone output — roughly 1.5 to 2-fold greater than the sum of each agent given separately. Whether this synergy holds at the lower doses used in human protocols remains an open question.

What the Animal and Human Data Actually Show

Most controlled dose-finding work for CJC-1295 comes from a small Phase I trial published by Teichman et al. (Growth Hormone & IGF Research, 2006). Healthy adults received single subcutaneous doses ranging from 30 to 120 µg/kg. Growth hormone and IGF-1 levels rose dose-dependently and remained elevated for 6-13 days post-injection. The 60 µg/kg dose produced a roughly 2-3 fold increase in mean 24-hour growth hormone concentration and a sustained IGF-1 rise of 1.5-fold over baseline. Injection site reactions occurred in about 20% of subjects; no serious adverse events were reported in this short-term study. Importantly, this trial used CJC-1295 alone — no secretagogue was co-administered.

For ipamorelin, published human data are thinner. A handful of small studies in elderly populations (unpublished or presented only at conferences) suggested that subcutaneous doses of 200-300 µg produced measurable growth hormone pulses without significant cortisol or prolactin elevation. Half-life was estimated at approximately 2 hours, consistent with rodent pharmacokinetic work. One conference abstract (Raun et al., Journal of Endocrinology, 1998) reported that ipamorelin at 18 µg/kg subcutaneously in Sprague-Dawley rats produced peak growth hormone levels at 30 minutes, returning to baseline by 3 hours.

No peer-reviewed, controlled human trial has evaluated CJC-1295 plus ipamorelin as a combination. Dosing protocols circulating in clinical and research communities are extrapolations from the monotherapy data above, adjusted downward for safety and stacked to avoid redundant receptor saturation. The most common practitioner-used regimen: CJC-1295 at 1-2 mg per week (roughly 15-30 µg/kg in a 70 kg adult), combined with ipamorelin at 200-300 µg per dose, administered 1-2 times daily. These figures are not derived from randomized trials; they reflect consensus among anti-aging clinics and self-experimenters, often guided by anecdotal tolerability rather than published dose-response curves.

Veterinary studies in swine and cattle have shown that repeated growth hormone secretagogue dosing over weeks increases lean mass and reduces fat deposition, but translation to human body composition outcomes remains speculative in the absence of placebo-controlled human trials with body composition endpoints.

Practical Dosing Parameters from Research and Clinical Use

Published and clinical dosing for CJC-1295 + ipamorelin typically follows one of two patterns: twice-weekly CJC-1295 combined with daily or twice-daily ipamorelin, or less commonly, both agents dosed together 3-5 times per week at lower individual amounts. For research purposes only, the following ranges appear in investigational protocols:

CJC-1295: 1-2 mg subcutaneously, once or twice per week. This translates to approximately 15-30 µg/kg per dose in a 70 kg individual, which sits below the 60 µg/kg used in the Teichman trial but extends exposure over time through repeated dosing. Some protocols reduce frequency to once weekly after an initial loading phase; others maintain twice-weekly dosing indefinitely. Subcutaneous injection into abdominal fat is standard, with absorption occurring over several hours.

Ipamorelin: 200-300 µg subcutaneously per dose, administered 1-2 times daily. Doses are often timed pre-workout or before sleep to align with natural growth hormone pulse windows, though evidence that timing significantly improves outcomes in humans is lacking. Because ipamorelin's half-life is short (approximately 2 hours), pulsatile dosing is considered preferable to sustained elevation — matching endogenous growth hormone release patterns.

Combination dosing: The most common approach pairs CJC-1295 at 1-2 mg twice weekly with ipamorelin at 200-300 µg daily or twice daily. Some users front-load CJC-1295 with slightly higher doses (2 mg on day 1, then 1 mg maintenance), though pharmacokinetic justification for this is weak given the peptide's long half-life. Total weekly CJC-1295 exposure typically ranges from 2-4 mg; total weekly ipamorelin exposure ranges from 1.4-4.2 mg depending on frequency.

Reconstitution and stability: Both peptides are supplied as lyophilized powders and reconstituted with bacteriostatic water. CJC-1295 is stable for approximately 28 days refrigerated post-reconstitution; ipamorelin degrades faster and should be used within 14-21 days. Freezing reconstituted peptide is not recommended, as freeze-thaw cycles can denature the active structure. Vials should be stored at 2-8°C and protected from light.

Injection technique: Subcutaneous administration uses a 0.3-0.5 mL insulin syringe with a 28-31 gauge needle. Injection sites should be rotated to reduce lipohypertrophy. Air bubbles must be purged to ensure accurate dosing, especially for ipamorelin, where the dose volume is small (often 0.2-0.3 mL).

Monitoring parameters: Practitioners monitoring these protocols typically check baseline and follow-up IGF-1 levels every 4-6 weeks. IGF-1 serves as a surrogate for growth hormone exposure, though it's an imperfect one — individual variation in hepatic IGF-1 synthesis means two people with identical growth hormone profiles can show different IGF-1 responses. Fasting glucose and HbA1c are sometimes monitored because chronic growth hormone elevation can impair insulin sensitivity in susceptible individuals, though this is more commonly seen with supraphysiologic growth hormone replacement than secretagogue use.

What the Combination Might Do, and What It Definitely Doesn't

The theoretical benefit of CJC-1295 plus ipamorelin is threefold: increased lean mass, reduced fat mass, and improved recovery markers. In rodent models and veterinary trials, GHS-R1a agonists combined with GHRH analogues increased nitrogen retention and lean tissue accretion over 4-8 week periods. Anecdotal reports from clinical use suggest modest improvements in sleep quality, skin thickness, and subjective recovery from training, though placebo-controlled data for these endpoints are absent.

What the combination does not do: it does not produce growth hormone levels comparable to exogenous recombinant human growth hormone (rhGH) replacement. Peak growth hormone from secretagogues typically reaches 2-5 ng/mL, whereas rhGH can push levels to 10-20 ng/mL or higher. This means secretagogue-driven effects are milder and slower to manifest. Body composition changes, if they occur, take months rather than weeks.

No published study has demonstrated fat loss from this combination in humans. Rodent and swine data suggest fat reduction is secondary to increased lipolysis and fatty acid oxidation driven by elevated growth hormone and IGF-1, but whether this translates meaningfully in adult humans eating ad libitum diets is unknown. Anecdotal reports of "recomposition" are common but lack the rigor of DEXA-measured body composition tracked in placebo-controlled trials.

Bone density changes take even longer — growth hormone and IGF-1 influence bone remodeling over months to years, and no long-term trial of this combination has evaluated fracture risk or bone mineral density as primary endpoints. Claims that secretagogue use accelerates bone healing are extrapolated from animal fracture models, not human orthopedic data.

Interactions, Tolerability, and What Goes Wrong

The most common side effect of CJC-1295 is injection site irritation — redness, swelling, or nodules that persist for several days. This occurs in roughly 20-30% of users based on Phase I trial data and clinical observation. Rotating injection sites reduces but does not eliminate this issue. Rarely, users report flu-like symptoms or transient joint pain in the first few weeks, which may reflect rapid shifts in fluid retention as IGF-1 rises.

Ipamorelin is generally better tolerated than older GHS-R1a agonists. Unlike GHRP-6, it does not produce significant hunger spikes; unlike Hexarelin, it does not desensitize the ghrelin receptor with chronic use (though data on this are limited beyond rodent studies). Mild water retention and carpal tunnel-like symptoms have been reported anecdotally but are uncommon at standard doses.

The combination does not appear to interact meaningfully with most medications, but caution is warranted in individuals using insulin or other glucose-lowering agents. Growth hormone is a counter-regulatory hormone — it opposes insulin's effects and can raise fasting glucose over time. Diabetics or pre-diabetics using this combination should monitor glucose closely, especially in the first 4-6 weeks.

Concurrent use of glucocorticoids (prednisone, dexamethasone) may blunt the growth hormone response to secretagogues, as cortisol suppresses GH release at the pituitary level. Conversely, thyroid hormone status affects IGF-1 production; hypothyroid individuals may see attenuated IGF-1 rises even with adequate growth hormone release.

FAQ

Q: How long does it take to see results from CJC-1295 and ipamorelin?

Measurable IGF-1 elevation occurs within 3-7 days of starting CJC-1295. Subjective changes like improved sleep or recovery are reported within 2-4 weeks. Body composition changes, if they occur, typically require 8-12 weeks of consistent dosing. Expecting rapid, dramatic shifts is unrealistic given the peptides' modest growth hormone output compared to exogenous rhGH.

Q: Can you take CJC-1295 and ipamorelin long-term?

No controlled human trial has evaluated safety beyond 12 weeks. Most clinical protocols cycle the combination — 12-16 weeks on, 4-8 weeks off — to reduce the theoretical risk of receptor downregulation or negative feedback on the growth hormone axis. Whether this cycling is necessary or effective is not established by data. For research purposes only, long-term use should be monitored with periodic IGF-1 and glucose checks.

Q: Is CJC-1295 without DAC better than the DAC version for this stack?

CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple daily doses to maintain GHRH signaling. Some users prefer this because it allows more precise control over growth hormone pulses and avoids the sustained elevation produced by the DAC version. However, the convenience of twice-weekly dosing with CJC-1295 DAC makes it the more common choice in practice. No head-to-head trial compares the two approaches for efficacy or safety.

Q: Why not just use growth hormone instead of secretagogues?

Cost and legality are the main barriers. Recombinant human growth hormone requires a prescription in most jurisdictions and costs significantly more than peptide secretagogues. Additionally, exogenous rhGH suppresses endogenous production through negative feedback, whereas secretagogues work with the body's existing machinery. Some researchers prefer secretagogues for this reason, though the trade-off is lower peak growth hormone levels and slower, subtler effects.

Q: Do you need to cycle ipamorelin to prevent receptor desensitization?

Rodent studies with continuous GHS-R1a agonist exposure (using compounds like Hexarelin) showed receptor downregulation after 4-6 weeks. Ipamorelin is thought to produce less desensitization due to its selectivity, but long-term human data are missing. Many protocols include 4-week breaks after 12-16 weeks of use as a precautionary measure, though whether this is necessary for ipamorelin specifically is not proven.

---

The information above is intended for research and educational purposes only. These peptides are not approved for human use outside of controlled clinical trials. Individuals considering their use should consult a qualified healthcare provider and comply with all applicable regulations. Long-term safety and efficacy in humans remain incompletely characterized.